Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Status Completed

Clinical Trial Summary

This trial evaluated the use of a tetravalent vaccine against dengue. Primary objectives: - To describe the humoral immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children. - To evaluate the safety of each vaccination with tetravalent dengue vaccine in the 4 age cohorts. - To evaluate the persistence of antibodies against dengue during 5 years after the first vaccination with tetravalent dengue vaccine in the 4 age cohorts.

Clinical Trial Description

Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00875524
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 2
Start date	March 2009
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04514107` - A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)	N/A
Completed	`NCT00788151` - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years	Phase 2
Completed	`NCT02510638` - The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia	N/A
Completed	`NCT01666652` - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults	Phase 1
Completed	`NCT01477671` - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children	N/A
Completed	`NCT01443247` - Role of Andi-d in Dengue Fever: a Pilot Study	N/A
Completed	`NCT00831012` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults	Phase 1
Completed	`NCT00089908` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults	Phase 1
Completed	`NCT01983553` - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed	`NCT01134263` - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia	Phase 3
Completed	`NCT02741128` - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults	Phase 2
Completed	`NCT03620487` - Detection of Dengue Virus in Plasma of Patients in Nepal
Recruiting	`NCT02608047` - Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou	N/A
Completed	`NCT02510690` - Factors Associated With Poor Dengue Outcomes in Malaysia	N/A
Completed	`NCT01550016` - International Research Consortium on Dengue Risk Assessment, Management, and Surveillance	N/A
Completed	`NCT01421732` - Laboratory Diagnosis and Prognosis of Severe Dengue	N/A
Completed	`NCT00993447` - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America	Phase 2
Completed	`NCT01224639` - Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever	Phase 1
Completed	`NCT01943825` - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine	Phase 2
Active, not recruiting	`NCT03465254` - Dengue Serostatus Study in the Philippines